Dover, United States
Xynomic Pharma, founded in 2016, is a US headquartered biopharmaceutical company with a strategic focus on in-licensing, developing, and commercializing oncology drug candidates in China, the US, and globally. With founding executives having past experience in top-tier companies like Schering, Eli Lilly, Merck, and Roche, the company leverages both its industry expertise and entrepreneurial acumen to build a robust clinical and pre-clinical oncology pipeline.
Xynomic Pharma strategically targets cancers with a high prevalence in its key markets and optimizes global resources to develop drugs efficiently in terms of cost and time. By combining its rich industry know-how with a comprehensive understanding of US-China dynamics, the company aims to accelerate its growth in the Biopharma, Biotechnology, and Pharmaceutical industries.
Following its Series B investment on 01 June 2018, Xynomic Pharma has garnered support from notable investors like Northern Light Venture Capital, Puhua Capital, Prosperico Ventures, Hakim Unique Internet, and Zhongshan Bison Healthcare Investment, firming its financial backing and future growth potential.
